Shorter TB treatment for people with HIV and low CD4 counts
Part of Immune system & allergy, Infections clinical trials.
This study tests a shorter treatment for active tuberculosis (TB) in people who also have HIV and a very low CD4 count. The goal is to see if the shorter regimen works as well as the standard one, which could mean less time on treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have HIV and a CD4 count below 100.
- You must have active tuberculosis (TB) in your lungs.
- You can start antiretroviral therapy (ART) for HIV and TB treatment at the same time.
- Your weight must be at least 40 kg (about 88 pounds).
- You cannot have certain other serious TB forms (like TB meningitis) or severe liver or kidney problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a shorter treatment for children with tuberculosis (TB) that is not drug-resistant. It aims to find out if a shorter regimen works as well as the standard longer one, making treatment easier for children and their families.
This trial tests a shorter treatment course (instead of the standard 6 months) for people with low-risk active TB in the lungs. It aims to see if the shorter regimen works just as well and has fewer side effects.
This trial tests a shorter treatment regimen for people with tuberculosis (TB) who don't have symptoms. If you have TB bacteria in your lungs but no cough, fever, night sweats, or weight loss, this study may offer a more convenient treatment option.
This study tests a shorter treatment for a type of TB that is resistant to rifampicin (a common TB medicine) but still sensitive to isoniazid. It aims to see if this shorter regimen is as effective as the current longer one, potentially making treatment less burdensome for patients.
This study tests whether a shorter course of TB treatment (4 months) works just as well as the standard longer course (6 months) for people whose chest X-ray suggests TB but whose sputum test does not confirm it. It aims to reduce treatment burden while keeping the cure rate high.
This study tests a new combination of two existing medicines (pyrazinamide and hydroxychloroquine) to see if it works as well as the current standard treatment for TB. If it works, it could mean fewer pills or a shorter treatment for patients with drug-sensitive TB.
Hear when a new Drug Susceptible Pulmonary Tuberculosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.